Datasheet: MCA1038F BATCH NUMBER 1707

| Description: | RAT ANTI DOG CD4:FITC |
|---------------|-----------------------|
| Specificity: | CD4 |
| Format: | FITC |
| Product Type: | Monoclonal Antibody |
| Clone: | YKIX302.9 |
| lsotype: | lgG2a |
| Quantity: | 100 TESTS |
| | |

Product Details

| Applications | This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-</u> | | | | | | | |
|-----------------------------------|--|------------------|-----------|-----------------------|-------------------------|--|--|--|
| | rad-antibodies.com/protocols. | | | | | | | |
| | Flow Cytometry | Yes | No | Not Determined | Suggested Dilution Neat | | | |
| | | | stad for | use in a particular t | | | | |
| | Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls. | | | | | | | |
| Target Species | Dog | | | | | | | |
| Product Form | Purified IgG conjugate | d to Fluoresco | ein Isoth | iocyanate Isomer 1 | (FITC) - liquid | | | |
| Max Ex/Em | Fluorophore | Excitation Ma | ax (nm) | Emission Max (nm) | | | | |
| | FITC | 490 | | 525 | | | | |
| Preparation | Purified IgG prepared supernatant | by affinity chro | omatogr | aphy on Protein G f | rom tissue culture | | | |
| Buffer Solution | Phosphate buffered sa | aline | | | | | | |
| Preservative Stabilisers | 0.09% Sodium Azide 1% Bovine Serum / | Albumin | | | | | | |
| Approx. Protein Concentrations | IgG concentration 0.1 | mg/ml | | | | | | |

| Immunogen | Canine concanavilin A activated T cell blasts. |
|----------------------------|---|
| External Database Links | UniProt: <u>P33705</u> <u>Related reagents</u> Entrez Gene: <u>403931</u> CD4 <u>Related reagents</u> |
| RRID | AB_321271 |
| Fusion Partners | Spleen cells from immunised DA rats were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line. |
| Specificity | Rat anti Dog CD4 antibody, clone YKIX302.9, is a monoclonal antibody specific for the canine CD4 cell surface antigen. Clone YKIX302.9 was clustered at the first Canine Leukocyte Antigen Workshop (CLAW) [Cobbold <i>et al.</i> 1992] along with clone CA13.1E4. Rat anti Dog CD4 antibody, clone YKIX302.9 partially depletes circulating T lymphocytes when administered <i>in vivo</i>, but alone is not sufficient to prolong allograft survival in a canine transplant model (Watson <i>et al.</i> 1993). Uniquely amongst mammals, canine CD4 is expressed by neutrophils as well as by lymphocyte subsets (Moore <i>et al.</i> 1992). |
| Flow Cytometry | Use 10ul of the suggested working dilution to label 10 ⁶ cells or 100ul whole blood. |
| References | Schaut, R.G. <i>et al.</i> (2016) Recovery of antigen-specific T cell responses from dogs infected with <i>Leishmania (L.) infantum</i> by use of vaccine associated TLR-agonist adjuvant. Vaccine. 34 (44): 5225-34. Gorman, S.D. <i>et al.</i> (1994) Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens. <u>Tissue Antigens. 43 (3): 184-8.</u> Watson, C.J. <i>et al.</i> (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog. <u>Br J Surg. 80 (11): 1389-92.</u> Papadogiannakis, E.I. <i>et al.</i> (2009) Determination of intracellular cytokines IFN-gamma and IL-4 in canine T lymphocytes by flow cytometry following whole-blood culture. <u>Can J Vet Res. 73 (2): 137-43.</u> Bauer, T.R. Jr. <i>et al.</i> (2006) Correction of the disease phenotype in canine leukocyte adhesion deficiency using <i>ex vivo</i> hematopoietic stem cell gene therapy. <u>Blood. 108: 3313-20.</u> Reis, A.B. <i>et al.</i> (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by <i>Leishmania chagasi.</i> <u>Clin Exp Immunol. 146: 303-11.</u> Araújo, M.S. <i>et al.</i> (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. <u>Vet Immunol Immunopathol. 141: 64-75.</u> Benyacoub, J. <i>et al.</i> (2003) Supplementation of food with <i>Enterococcus faecium</i> (SF68) stimulates immune functions in young dogs. <u>J Nutr. 133: 1158-62.</u> |

9. Bund, D. *et al.* (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies. <u>Cell Immunol. 263: 88-98.</u>
10. Estrela-Lima, A. *et al.* (2010) Immunophenotypic features of tumor infiltrating

lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. <u>BMC Cancer. 10: 256.</u>

11. Out, T.A. *et al.* (2002) Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs. <u>Immunology. 105: 499-508.</u>

12. Boggiatto, P.M. *et al.* (2010) Immunologic indicators of clinical progression during canine *Leishmania infantum* infection. <u>Clin Vaccine Immunol. 17: 267-73.</u>

13. Mitchell, L. *et al.* (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. <u>J Vet Intern Med. 26: 355-62.</u>

14. Tominaga, M. *et al.* (2010) Flow cytometric analysis of peripheral blood and tumorinfiltrating regulatory T cells in dogs with oral malignant melanoma. <u>J Vet Diagn Invest. 22:</u> <u>438-41.</u>

15. Figueiredo, M.M. *et al.* (2014) Expression of Regulatory T Cells in Jejunum, Colon, and Cervical and Mesenteric Lymph Nodes of Dogs Naturally Infected with *Leishmania infantum*. <u>Infect Immun. 82: 3704-12.</u>

16. Aresu, L. *et al.* (2014) VEGF and MMP-9: biomarkers for canine lymphoma. <u>Vet Comp</u> <u>Oncol. 12: 29-36.</u>

Costa-Pereira, C. *et al.* (2015) One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis. <u>BMC Vet Res. 11 (1): 92.</u>
 Hauck, V. *et al.* (2016) Increased numbers of FoxP3-expressing CD4(+) CD25(+) regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity. <u>Vet Dermatol. 27 (1): 26-e9.</u>

19. Riondato, F. *et al.* (2015) Analytical and diagnostic validation of a flow cytometric strategy to quantify blood and marrow infiltration in dogs with large b-cell lymphoma. Cytometry B Clin Cytom. Dec 13. [Epub ahead of print]

20. Miranda, S. *et al.* (2007) Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol. <u>Vet Parasitol.</u> <u>144 (3-4): 251-60.</u>

21. Yamaya, Y. & Watari, T. (2015) Increased proportions of CCR4(+) cells among peripheral blood CD4(+) cells and serum levels of allergen-specific IgE antibody in canine chronic rhinitis and bronchitis. <u>J Vet Med Sci. 77 (4): 421-5.</u>

22. Schaut, R.G. *et al.* (2016) Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis. J Immunol. 196 (10): 4100-9.

23. Tagawa, M. *et al.* (2016) Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma. <u>PLoS One. 11 (2): e0150030.</u>
24. Munhoz, T.D. *et al.* (2016) Regulatory T cells in dogs with multicentric lymphoma:

peripheral blood quantification at diagnosis and after initial stage chemotherapy <u>Arq. Bras.</u> <u>Med. Vet. Zootec. 68 (1): 1-9.</u>

25. Miller, J. *et al.* (2015) Humoral and Cellular Immune Response in Canine Hypothyroidism. <u>J Comp Pathol. 153 (1): 28-37.</u>

26. Duz AL *et al.* (2014) The Tcl and Tcll *Trypanosoma cruzi* experimental infections induce distinct immune responses and cardiac fibrosis in dogs. <u>Mem Inst Oswaldo Cruz.</u> <u>109 (8): 1005-13.</u>

27. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. <u>Vet Immunol Immunopathol. 159 (1-2): 91-6.</u>

28. Viana, K.F. *et al.* (2015) Setting the proportion of CD4+ and CD8+ T-cells co-cultured with canine macrophages infected with *Leishmania chagasi*. <u>Vet Parasitol. 211 (3-4)</u>: 124-32.

29. Viana, K.F. *et al.* (2016) Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-). <u>Parasit Vectors. 9: 250.</u>

30. Michael HT *et al.* (2013) Isolation and characterization of canine natural killer cells. <u>Vet</u> <u>Immunol Immunopathol. 155 (3): 211-7.</u>

31. Mitchell, L. *et al.* (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma. <u>Vet Immunol</u> <u>Immunopathol. 145 (3-4): 597-603.</u>

32. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. <u>Immunobiology. 221 (1): 12-22.</u>

33. Deravi, N. *et al.* (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes. <u>Vet Immunol Immunopathol. 191: 5-13.</u>

34. Bahamondes, F. *et al.* (2017) Omental adipose tissue is a more suitable source of canine Mesenchymal stem cells. <u>BMC Vet Res. 13 (1): 166.</u>

35. Pinheiro, D. (2011) Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog. <u>Immunology. 132: 111-22.</u>

36. Withers, S.S. *et al.* (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs. <u>Dev Comp Immunol. 87: 64-74.</u>

37. Declue, A.E. *et al.* (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy. <u>BMC Vet Res.</u> <u>14 (1): 119.</u>

38. DaSilva, A.V.A. *et al.* (2018) Morphophysiological changes in the splenic extracellular matrix of *Leishmania infantum*-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens. <u>PLoS Negl Trop Dis. 12 (4):</u> <u>e0006445.</u>

39. Roatt, B.M. *et al.* (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. <u>Front Immunol. 8: 217.</u>

40. Lisiecka. U. *et al.* (2019) Evaluation of T regulatory lymphocytes and serum concentration of selected cytokines in dogs with perianal tumors. <u>Vet Immunol Immunopathol. 207: 10-17.</u>

41. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. <u>BMC Vet Res. 9: 94.</u>
42. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune[®], and Leish-Tec[®] Vaccines against Canine Visceral Leishmaniasis. <u>Vaccines</u> (Basel). 8 (4)Nov 17 [Epub ahead of print].

Storage Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

| | Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. | | | |
|----------------------------------|---|--|--|--|
| Guarantee | 12 months from date of despatch | | | |
| Health And Safety Information | Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA1038F 10041 | | | |
| Regulatory | For research purposes only | | | |
| | | | | |

Related Products

Recommended Negative Controls

RAT IgG2a NEGATIVE CONTROL:FITC (MCA6005F) RAT IgG2a NEGATIVE CONTROL:FITC (MCA1212F)

| North & South America | Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-r | Worldwide ad.com | Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-ra | Europe d.com | Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com | | |
|---|--|---------------------|---|-----------------|--|--|--|
| To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M364686:200529' | | | | | | | |

Printed on 14 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint